They found that the PD-1 blockade therapy enhances the proliferation of T cells, B cells, and myeloid-derived suppressive cells (MDSCs) in the tumour site, being CD8+ memory T cells the main T-cell phenotype in patients with therapy response. This evidence concerns the gene PDCD1 and neoplasm.